Post(neo)adjuvante Therapiekonzepte – Möglichkeiten der Therapieoptimierung

Natalia Krawczyk; Tanja Fehm; Elmar Stickeler; Christoph Thomssen; Marc Thill; Maggie Banys-Paluchowski

doi:10.1007/s00129-022-04932-7

Post(neo)adjuvante Therapiekonzepte – Möglichkeiten der Therapieoptimierung

Translated title of the contribution: Post(neo)adjuvant therapy concepts—Possibilities for treatment optimization

Natalia Krawczyk^*, Tanja Fehm, Elmar Stickeler, Christoph Thomssen, Marc Thill, Maggie Banys-Paluchowski

^*Corresponding author for this work

Abstract

Modern systemic treatment for breast cancer is based on the tumor subtype and the individual risk of recurrence. In the case of high-risk situations chemotherapy is usually administered, sometimes combined with targeted substances and preferably in the neoadjuvant setting. Due to the neoadjuvant concept, the response to treatment can be postoperatively assessed and post(neo)adjuvant treatment can be individually adapted. In triple negative tumors, in addition to post(neo)adjuvant treatment with capecitabine, new targeted substances, such as immune checkpoint inhibitors or in cases of BRCA germline mutations, the poly adenosine diphosphate ribose polymerase (PARP) inhibitor olaparib can be implemented. Patients with HER2 positive disease and non-pathological complete remission (pCR) are recommended to switch to trastuzumab emtansine (TDM1). In cases of hormone receptor positive HER2 negative tumors the cyclin-dependent kinases (CDK) 4/6 inhibitor abemaciclib and for those with BRCA germline mutations the PARP inhibitor olaparib as post(neo)adjuvant escalation strategies are available.

Translated title of the contribution	Post(neo)adjuvant therapy concepts—Possibilities for treatment optimization
Original language	German
Journal	Gynakologe
Volume	55
Issue number	5
Pages (from-to)	324-333
Number of pages	10
ISSN	0017-5994
DOIs	https://doi.org/10.1007/s00129-022-04932-7
Publication status	Published - 05.2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)

DFG Research Classification Scheme

2.22-14 Hematology, Oncology
2.22-21 Gynaecology and Obstetrics

Access to Document

10.1007/s00129-022-04932-7

Cite this

@article{7acf88e522c64c168c2e5a34e5d5cf27,

title = "Post(neo)adjuvante Therapiekonzepte – M{\"o}glichkeiten der Therapieoptimierung",

abstract = "Modern systemic treatment for breast cancer is based on the tumor subtype and the individual risk of recurrence. In the case of high-risk situations chemotherapy is usually administered, sometimes combined with targeted substances and preferably in the neoadjuvant setting. Due to the neoadjuvant concept, the response to treatment can be postoperatively assessed and post(neo)adjuvant treatment can be individually adapted. In triple negative tumors, in addition to post(neo)adjuvant treatment with capecitabine, new targeted substances, such as immune checkpoint inhibitors or in cases of BRCA germline mutations, the poly adenosine diphosphate ribose polymerase (PARP) inhibitor olaparib can be implemented. Patients with HER2 positive disease and non-pathological complete remission (pCR) are recommended to switch to trastuzumab emtansine (TDM1). In cases of hormone receptor positive HER2 negative tumors the cyclin-dependent kinases (CDK) 4/6 inhibitor abemaciclib and for those with BRCA germline mutations the PARP inhibitor olaparib as post(neo)adjuvant escalation strategies are available.",

author = "Natalia Krawczyk and Tanja Fehm and Elmar Stickeler and Christoph Thomssen and Marc Thill and Maggie Banys-Paluchowski",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.",

year = "2022",

month = may,

doi = "10.1007/s00129-022-04932-7",

language = "Deutsch",

volume = "55",

pages = "324--333",

journal = "Gynakologe",

issn = "0017-5994",

publisher = "Springer Medizin",

number = "5",

}

TY - JOUR

T1 - Post(neo)adjuvante Therapiekonzepte – Möglichkeiten der Therapieoptimierung

AU - Krawczyk, Natalia

AU - Fehm, Tanja

AU - Stickeler, Elmar

AU - Thomssen, Christoph

AU - Thill, Marc

AU - Banys-Paluchowski, Maggie

PY - 2022/5

Y1 - 2022/5

N2 - Modern systemic treatment for breast cancer is based on the tumor subtype and the individual risk of recurrence. In the case of high-risk situations chemotherapy is usually administered, sometimes combined with targeted substances and preferably in the neoadjuvant setting. Due to the neoadjuvant concept, the response to treatment can be postoperatively assessed and post(neo)adjuvant treatment can be individually adapted. In triple negative tumors, in addition to post(neo)adjuvant treatment with capecitabine, new targeted substances, such as immune checkpoint inhibitors or in cases of BRCA germline mutations, the poly adenosine diphosphate ribose polymerase (PARP) inhibitor olaparib can be implemented. Patients with HER2 positive disease and non-pathological complete remission (pCR) are recommended to switch to trastuzumab emtansine (TDM1). In cases of hormone receptor positive HER2 negative tumors the cyclin-dependent kinases (CDK) 4/6 inhibitor abemaciclib and for those with BRCA germline mutations the PARP inhibitor olaparib as post(neo)adjuvant escalation strategies are available.

AB - Modern systemic treatment for breast cancer is based on the tumor subtype and the individual risk of recurrence. In the case of high-risk situations chemotherapy is usually administered, sometimes combined with targeted substances and preferably in the neoadjuvant setting. Due to the neoadjuvant concept, the response to treatment can be postoperatively assessed and post(neo)adjuvant treatment can be individually adapted. In triple negative tumors, in addition to post(neo)adjuvant treatment with capecitabine, new targeted substances, such as immune checkpoint inhibitors or in cases of BRCA germline mutations, the poly adenosine diphosphate ribose polymerase (PARP) inhibitor olaparib can be implemented. Patients with HER2 positive disease and non-pathological complete remission (pCR) are recommended to switch to trastuzumab emtansine (TDM1). In cases of hormone receptor positive HER2 negative tumors the cyclin-dependent kinases (CDK) 4/6 inhibitor abemaciclib and for those with BRCA germline mutations the PARP inhibitor olaparib as post(neo)adjuvant escalation strategies are available.

UR - https://www.scopus.com/pages/publications/85128829591

U2 - 10.1007/s00129-022-04932-7

DO - 10.1007/s00129-022-04932-7

M3 - Übersichtsarbeiten

AN - SCOPUS:85128829591

SN - 0017-5994

VL - 55

SP - 324

EP - 333

JO - Gynakologe

JF - Gynakologe

IS - 5

ER -